# Biologics CDMO Secondary Packaging Market to Hit USD 5.50 Billion by 2034

The **Biologics CDMO (Contract Development and Manufacturing Organization) Secondary Packaging Market** is set to experience robust growth over the next decade. Valued at **USD 2.59 billion in 2025**, it is projected to reach **USD 5.50 billion by 2034**, expanding at a **CAGR of 8.75%** from 2025 to 2034.

---

## üìä Market Revenue Forecast: 2023‚Äì2034

The rising demand for outsourced packaging solutions and the surge in biologics manufacturing are pivotal drivers of this market. **Secondary packaging** ensures the integrity, safety, and traceability of sensitive biological products through their distribution cycle.

---

## üåê Market Overview

Secondary packaging in the biologics space encompasses:

- **Cartonization**
- **Labeling**
- **Barcoding**
- Other post-primary packaging processes

It plays a crucial role in **safely transporting injectable drugs, vaccines, and biosimilars**, which often require strict **temperature-controlled environments**.

Biologics supported by this sector include:

- Gene therapies
- Monoclonal antibodies
- mRNA vaccines
- Biosimilars

### Key Drivers:
- Increasing prevalence of chronic, infectious, and genetic disorders
- Higher demand for tamper-evident and regulatory-compliant packaging
- Emphasis on global cold chain logistics

---

## üîë Key Market Insights

- **North America** is expected to dominate the market in 2024 due to a strong CDMO infrastructure.
- **Asia Pacific** is projected to register the fastest growth rate, driven by regional pharmaceutical investments.
- By **packaging type**, **boxes** held the largest market share in 2024.
- **Ampoules** were the leading primary packaging solution in 2024, highlighting their importance in biologic drug delivery.

---

## üè¢ Major Industry Players

Innovations in secondary packaging are being led by:

- **WuXi Biologics (Cayman) Inc.**
- **FUJIFILM Diosynth Biotechnologies U.S.A. Inc.**
- **Samsung Biologics Co. Ltd.**
- **Thermo Fisher Scientific Inc.**
- **Rentschler Biopharma SE**

These players are enhancing global standards for biologics packaging with technologies that emphasize **compliance**, **safety**, and **efficiency**.

---

## üì¶ Importance of Secondary Packaging

Secondary packaging offers multiple benefits:

- Ensures **tamper evidence**
- Enhances **supply chain traceability**
- Supports **regulatory compliance**
- Extends **shelf life**, especially for thermally sensitive biologics

---

## üìà Future Outlook

As the biologics industry matures, the **outsourcing of packaging to specialized CDMOs** is expected to gain momentum. Key benefits include:

- **Scalability**
- **Cost-efficiency**
- **Streamlined compliance management**
Source: [https://www.towardspackaging.com/insights/biologics-cdmo-secondary-packaging-market-sizing]

The increasing complexity of biologics underscores the need for **advanced secondary packaging solutions**, positioning CDMOs as critical partners for pharmaceutical firms worldwide.
